Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Induced Pluripotent Stem Cells01:13

Induced Pluripotent Stem Cells

26.2K
Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore...
26.2K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

5.1K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early detection of Niemann-pick disease type C with cataplexy and orexin levels: continuous observation with and without Miglustat.

Orphanet journal of rare diseases·2020
Same author

Perirenal fat thickness as a predictor of postoperative complications after laparoscopic distal gastrectomy for gastric cancer.

BJS open·2020
Same author

Morphological lymphocytic reaction, patient prognosis and PD-1 expression after surgical resection for oesophageal cancer.

The British journal of surgery·2019
Same author

Laparoscopic sigmoidectomy and double-stapling technique anastomosis via needlescopic surgery - a video vignette.

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2018
Same author

Platelet production from induced pluripotent stem cells.

Journal of thrombosis and haemostasis : JTH·2017
Same author

Manipulating megakaryocytes to manufacture platelets ex vivo.

Journal of thrombosis and haemostasis : JTH·2015

Related Experiment Video

Updated: Dec 6, 2025

Generation of Human Induced Pluripotent Stem Cells from Peripheral Blood Using the STEMCCA Lentiviral Vector
12:03

Generation of Human Induced Pluripotent Stem Cells from Peripheral Blood Using the STEMCCA Lentiviral Vector

Published on: October 31, 2012

27.2K

[Novel platelet pharming using human induced pluripotent stem cells].

C Flahou1, N Sugimoto1, K Eto1,2

  • 1Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, 53, Kawahara-cho, 606-8507 Shogoin, Sakyo-ku, Kyoto, Japon.

Bulletin De L'Academie Nationale De Medecine
|October 5, 2020
PubMed
Summary
This summary is machine-generated.

Ex vivo platelet production using induced pluripotent stem cells (iPSCs) offers a safe and on-demand alternative to traditional transfusions. This approach could revolutionize platelet availability and reduce immune complications.

Keywords:
BioreactorsInduced pluripotent stem cellsMegakaryocytePlatelet transfusion

More Related Videos

Preparation of Pooled Human Platelet Lysate pHPL as an Efficient Supplement for Animal Serum-Free Human Stem Cell Cultures
08:32

Preparation of Pooled Human Platelet Lysate pHPL as an Efficient Supplement for Animal Serum-Free Human Stem Cell Cultures

Published on: October 30, 2009

25.8K
Induced Pluripotent Stem Cell Generation from Blood Cells Using Sendai Virus and Centrifugation
09:57

Induced Pluripotent Stem Cell Generation from Blood Cells Using Sendai Virus and Centrifugation

Published on: December 21, 2016

14.9K

Related Experiment Videos

Last Updated: Dec 6, 2025

Generation of Human Induced Pluripotent Stem Cells from Peripheral Blood Using the STEMCCA Lentiviral Vector
12:03

Generation of Human Induced Pluripotent Stem Cells from Peripheral Blood Using the STEMCCA Lentiviral Vector

Published on: October 31, 2012

27.2K
Preparation of Pooled Human Platelet Lysate pHPL as an Efficient Supplement for Animal Serum-Free Human Stem Cell Cultures
08:32

Preparation of Pooled Human Platelet Lysate pHPL as an Efficient Supplement for Animal Serum-Free Human Stem Cell Cultures

Published on: October 30, 2009

25.8K
Induced Pluripotent Stem Cell Generation from Blood Cells Using Sendai Virus and Centrifugation
09:57

Induced Pluripotent Stem Cell Generation from Blood Cells Using Sendai Virus and Centrifugation

Published on: December 21, 2016

14.9K

Area of Science:

  • Stem cell biology
  • Hematology
  • Biotechnology

Context:

  • Current platelet transfusion products face limitations in supply and safety.
  • Induced pluripotent stem cells (iPSCs) offer a promising source for platelet generation due to their self-renewal and accessibility.
  • Existing megakaryocyte (MK) lines derived from iPSCs exhibit robust proliferation and cryopreservation capabilities.

Purpose:

  • To review the advancements in ex vivo platelet production from iPSCs for clinical applications.
  • To highlight the potential of iPSC-derived platelets in addressing transfusion-related challenges.
  • To discuss the development of universal platelet products through genetic manipulation.

Summary:

  • Human iPSCs can be differentiated into expandable, cryopreservable megakaryocyte (MK) lines suitable for Good Manufacturing Practice (GMP) grade platelet production.
  • Advances in bioreactor technology and thrombopoiesis-promoting substances enhance the efficiency and quality of ex vivo generated platelets.
  • Genetic modification of iPSC-derived platelets, including HLA deletion, can mitigate alloimmune complications and create universal donor products.

Impact:

  • iPSC-derived platelets promise to ensure on-demand availability and enhance safety by minimizing blood-borne infection risks.
  • The development of autologous and HLA-compatible platelets from iPSCs can resolve transfusion-related alloimmune complications.
  • Industrial-scale production of HLA-deleted platelets could establish a universal product, revolutionizing the blood transfusion system.